NEN in a dish: A patient-derived organoid biobank illuminates potential novel therapeutic opportunities for neuroendocrine neoplasms

Stefanie Gerstberger; Karuna Ganesh

doi:10.1016/j.ccell.2023.11.006

NEN in a dish: A patient-derived organoid biobank illuminates potential novel therapeutic opportunities for neuroendocrine neoplasms

Cancer Cell. 2023 Dec 11;41(12):2014-2016. doi: 10.1016/j.ccell.2023.11.006.

Authors

Stefanie Gerstberger¹, Karuna Ganesh²

Affiliations

¹ Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
² Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Molecular Pharmacology Program, Sloan Kettering Institute, New York, NY 10065, USA. Electronic address: [email protected].

PMID: 38086333
DOI: 10.1016/j.ccell.2023.11.006

Abstract

Neuroendocrine neoplasms are rare cancers with limited treatment options and preclinical models. In this issue of Cancer Cell, Dayton et al. establish a patient-derived tumor organoid biobank encompassing pulmonary low-grade neuroendocrine tumors (LNETs) and high-grade neuroendocrine carcinomas (LCNECs), identifying novel biomarker-dependent therapeutic vulnerabilities using niche perturbation and drug response assays.

Publication types

Comment

MeSH terms

Biological Specimen Banks
Carcinoma, Neuroendocrine* / drug therapy
Carcinoma, Neuroendocrine* / genetics
Humans
Lung Neoplasms* / pathology
Neuroendocrine Tumors* / drug therapy
Neuroendocrine Tumors* / genetics
Neuroendocrine Tumors* / pathology

Grants and funding

U54 CA209975/CA/NCI NIH HHS/United States